Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma (GBM)
Primary Purpose
Glioblastoma
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
New delineation approach
Sponsored by
About this trial
This is an interventional treatment trial for Glioblastoma focused on measuring Radiotherapy, clinical target volume, Glioblastoma multiforme (GBM), radiation volume, the white matter tracts.
Eligibility Criteria
Inclusion Criteria:
- Age between 18-70 years
- performance status of 0-1 (Eastern Cooperative Oncology Group performance status)
- histologically confirmed glioblastoma
- no cerebrospinal fluid and distant metastatic disease
- All patients had adequate hematologic, hepatic, and renal function.
Exclusion Criteria:
- younger than 18 years;
- patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
New delineation approach (NDA)group
Arm Description
use a new method for clinical target volume delineation by referencing the nerve fiber bundles
Outcomes
Primary Outcome Measures
Overall survival (OS)
Time from the start of treatment to death due to the disease
Secondary Outcome Measures
recurrence-free survival (RFS)
Time from the start of treatment to recurrence
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05512195
Brief Title
Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma
Acronym
GBM
Official Title
Safety and Efficacy of a New Approach to Delineating Clinical Target Volume by Referencing the Nerve Fiber Bundles for Radiotherapy of Glioblastoma
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2022 (Anticipated)
Primary Completion Date
September 1, 2024 (Anticipated)
Study Completion Date
August 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zhongnan Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Radiotherapy (RT) is one of the most important local treatments besides surgery, but currently, no consensus has been made regarding the optimal radiation volume for high grade gliomas. The most main growth characteristics of glioblastoma is infiltrative growth through the white matter tracts, regions along the white matter tracts especially at the direction of the main fiber bundles would have a higher risk of microscopic tumor cell dissemination. However, in current practice, recommends for the CTV definition is adding a 2 cm symmetrical margin to GTV or peritumoral edema in all directions, which hardly account for the growth characteristics of gliomas that are known from histopathological findings.
Detailed Description
Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded.
Eligible patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen(75mg/m2 per day during RT), followed by 6 additional cycles of TMZ. (150 mg/m2 for the first cycle and 200 mg/m2 for the 2-6th cycles, on days 1-5, every 4 weeks) .
The investigators established a detailed protocol for target delineation of the CTV based on brain anatomy, white mater fiber tracts distribution and the growth patterns of tumor. Briefly, along the directions of the main nerve fiber bundles ,the CTV is defined as peritumoral edema plus 1cm. while in other directions, the CTV is defined as GTV plus 2cm and should be adjusted to anatomical borders such as the skull (0 mm, using bone window), ventricles (5 mm), falx (0 mm), tentorium cerebelli (0 mm), visual pathway/optic chiasm and brainstem (each 0 mm) and modified to include all regions of abnormal T2/FLAIR MRI signal. Deep brain white matter is the focus for RT target contour, regions of normal uninvolved gray matter should be modified to be protected.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioblastoma
Keywords
Radiotherapy, clinical target volume, Glioblastoma multiforme (GBM), radiation volume, the white matter tracts.
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
New delineation approach (NDA)group
Arm Type
Experimental
Arm Description
use a new method for clinical target volume delineation by referencing the nerve fiber bundles
Intervention Type
Radiation
Intervention Name(s)
New delineation approach
Intervention Description
New delineation approach
Primary Outcome Measure Information:
Title
Overall survival (OS)
Description
Time from the start of treatment to death due to the disease
Time Frame
2 years
Secondary Outcome Measure Information:
Title
recurrence-free survival (RFS)
Description
Time from the start of treatment to recurrence
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 18-70 years
performance status of 0-1 (Eastern Cooperative Oncology Group performance status)
histologically confirmed glioblastoma
no cerebrospinal fluid and distant metastatic disease
All patients had adequate hematologic, hepatic, and renal function.
Exclusion Criteria:
younger than 18 years;
patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma
We'll reach out to this number within 24 hrs